Long-term administration of quarterly IV ibandronate is effective and well tolerated in postmenopausal osteoporosis: 5-year data from the DIVA study long-term extension

Osteoporosis International

Volumn 23, Issue 6, 2012, Pages 1769-1778

  Bianchi, G ^a   Czerwinski, E ^b   Kenwright, A ^c   Burdeska, A ^d   Recker, R R ^e   Felsenberg, D ^f  

^a Division of Rheumatology   (Italy)

^b Krakowskie Centrum Medyczne   (Poland)

^c ROCHE PRODUCTS LTD   (United Kingdom)

^d F HOFFMANN LA ROCHE LTD   (Switzerland)

^e CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f HUMBOLDT UNIVERSITY   (Germany)

Author keywords

Bisphosphonate; Clinical study; Ibandronate; Intravenous; Long term treatment; Postmenopausal osteoporosis

Indexed keywords

IBANDRONIC ACID; PLACEBO;

ADULT; AGED; ARTHRALGIA; ARTICLE; BACKACHE; BODY MASS; BONE PAIN; BONE TURNOVER; BRONCHITIS; CONSTIPATION; CONTROLLED STUDY; CYSTITIS; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; DUAL ENERGY X RAY ABSORPTIOMETRY; DYSPEPSIA; FEMALE; FLU LIKE SYNDROME; GASTRITIS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INFLUENZA; LONG TERM CARE; LUMBAR SPINE; MAJOR CLINICAL STUDY; MUSCULOSKELETAL PAIN; MYALGIA; OSTEOARTHRITIS; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; TREATMENT DURATION; UPPER ABDOMINAL PAIN; URINARY TRACT INFECTION;

ABSORPTIOMETRY, PHOTON; ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LONGITUDINAL STUDIES; LUMBAR VERTEBRAE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; TREATMENT OUTCOME;

EID: 84863617923     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-011-1793-9     Document Type: Article

References (40)

1. NIH Consensus Statement (2000) Osteoporos Prev Diagn Ther 17 (1):27-29.
2. Cramer JA, Gold DT, Silverman SL, Lewiecki EM (2007) A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int 18:1023-1031. (Pubitemid 47019996)
3. Landfeldt E, Ström O, Robbins S, Borgström F (2011) Adherence to treatment of primary osteoporosis and its association to fractures-the Swedish Adherence Register Analysis (SARA). Osteoporos Int (in press).
4. Reginster J-Y, Rabenda V (2006) Patient preference in the management of postmenopausal osteoporosis with bisphosphonates. Clin Interv Aging 1:415-423.
5. Emkey R, Koltun W, Beusterien K, Seidman L, Kivitz A, Devas V, Masanauskaite D (2005) Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO). Curr Med Res Opin 21:1895-1903. (Pubitemid 41803098)
6. Hadji P, Minne H, Pfeifer M, Bourgeois P, Fardellone P, Licata A, Devas V, Masanauskaite D, Barrett-Connor E (2008) Treatment preference for monthly oral ibandronate and weekly oral alendronate in women with postmenopausal osteoporosis: a randomized, crossover study (BALTO II). Joint Bone Spine 75:303-310.
7. Cooper A, Drake J, Brankin E, Investigators PERSIST (2006) Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study. Int J Clin Pract 60:896-905. (Pubitemid 44082279)
8. Barrett J, Worth E, Bauss F (2004) Ibandronate: a clinical pharmacological and pharmacokinetic update. J Clin Pharmacol 44:951-965. (Pubitemid 39096810)
9. Delmas PD, Adami S, Strugala C, Stakkestad JA, Reginster JY, Felsenberg D, Christiansen C, Civitelli R, Drezner MK, Recker RR, Bolognese M, Hughes C, Masanauskaite D, Ward P, Sambrook P, Reid DM (2006) Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum 54:1838-1846. (Pubitemid 43877933)
10. Eisman JA, Civitelli R, Adami S, Czerwinski E, Recknor C, Prince R, Reginster JY, Zaidi M, Felsenberg D, Hughes C, Mairon N, Masanauskaite D, Reid DM, Delmas PD, Recker RR (2008) Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study. J Rheumatol 35:488-497. (Pubitemid 351374427)
11. Geusens P (2009) Bisphosphonates for postmenopausal osteoporosis: determining duration of treatment. Curr Osteoporos Rep 7:12-17.
12. Bone HG, Hosking D, Devogelaer J-P, Tucci JR, Emkey RD, Tonino RP, Rodriguez-Portales JA, Downs RW, Gupta J, Santora AC, Liberman UA, Alendronate Phase III Osteoporosis Treatment Study Group (2004) Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350:1189-1199. (Pubitemid 38339363)
13. Mellström DD, Sörensen OH, Goemaere S, Roux C, Johnson TD, Chines AA (2004) Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int 75:462-468. (Pubitemid 40174503)
14. Black D, Reid I, Cauley J, Boonen S, Cosman F, Leung PC, Lakatos P, Man Z, Cummings S, Hue T, Ruzycky M-E, Martinez R, Su G, Bucci-Rechtweg C, Eastell R (2010) The effect of 3 versus 6 years of zoledronic acid treatment in osteoporosis: a randomized extension to the HORIZON Pivotal Fracture Trial (PFT). J Bone Miner Res 25(SUPPL. 1):1070. Available at http://www.asbmr.org/ Meetings/AnnualMeeting/AbstractDetail.aspx? aid=4781a020-dc3a-46be-b49d- f706b5509c4e. Accessed 13 January 2011.
15. Felsenberg D, Czerwinski E, Stakkestad J, Neate C, Masanauskaite D, Reginster JY (2009) Efficacy of monthly oral ibandronate is maintained over 5 years: the MOBILE LTE study. Osteoporos Int 20 (SUPPL.1):S15, Abstract OC32.
16. Garnero P, Borel O, Delmas PD (2001) Evaluation of a fully automated serum assay for C-terminal cross-linking telopeptide of type I collagen in osteoporosis. Clin Chem 47:694-702. (Pubitemid 32275813)
17. Garnero P, Vergnaud P, Hoyle N (2008) Evaluation of a fully automated serum assay for total N-terminal propeptide of type I collagen in postmenopausal osteoporosis. Clin Chem 54:188-196. (Pubitemid 351182613)
18. Cranney A, Wells GA, Yetisir E, Adami S, Cooper C, Delmas PD, Miller PD, Papapoulos S, Reginster JY, Sambrook PN, Silverman S, Siris E, Adachi JD (2009) Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data. Osteoporos Int 20:291-297.
19. Chesnut CH, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A, Felsenberg D, Huss H, Gilbride J, Schimmer RC, Delmas PD, for the Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE) (2004) Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19:1241-1249. (Pubitemid 41094364)
20. Sebba AL, Emkey RD, Kohles JD, Sambrook PN (2009) Ibandronate dose response is associated with increases in bone mineral density and reductions in clinical fractures: results of a meta-analysis. Bone 44:423-427.
21. Brown JP, Albert C, Nassar BA, Adachi JD, Cole D, Davison KS, Dooley KC, Don-Wauchope A, Douville P, Hanley DA, Jamal SA, Josse R, Kaiser S, Krahn J, Krause R, Kremer R, Lepage R, Letendre E, Morin S, Ooi DS, Papaioaonnou A, Ste-Marie LG (2009) Bone turnover markers in the management of postmenopausal osteoporosis. Clin Biochem 42:929-942.
22. Papapoulos SE, Schimmer RC (2007) Changes in bone remodeling and antifracture efficacy of intermittent bisphosphonate therapy: implications from clinical studies with ibandronate. Ann Rheum Dis 66:853-858. (Pubitemid 46999783)
23. Croom KF, Scott LJ (2006) Intravenous ibandronate: in the treatment of osteoporosis. Drugs 66:1593-1601. (Pubitemid 44373745)
24. Strampel W, Emkey R, Civitelli R (2007) Safety considerations with bisphosphonates for the treatment of osteoporosis. Drug Saf 30:755-763. (Pubitemid 47351214)
25. Papapetrou PD (2009) Bisphosphonate-associated adverse events. Hormones 8:96-110.
26. Klawansky S, Komaroff E, Cavanaugh PF Jr, Mitchell DY, Gordon MJ, Connelly JE, Ross SD (2003) Relationship between age, renal function and bone mineral density in the US population. Osteoporos Int 14:570-576. (Pubitemid 36975556)
27. Watts NB, Diab DL (2010) Long-term use of bisphosphonates in osteoporosis. J Clin Endocrinol Metab 95:1555-1565.
28. Reid IR (2009) Osteonecrosis of the jaw-who gets it, and why? Bone 44:4-10.
29. Wimalawansa SJ (2008) Insight into bisphosphonate-associated osteomyelitis of the jaw: pathophysiology, mechanisms and clinical management. Expert Opin Drug Saf 7:491-512.
30. Sayed-Noor AS, Sjödén GO (2010) Case reports: two femoral insufficiency fractures after long-term alendronate therapy. Clin Orthop Relat Res 467:1921-1926.
31. Odvina CV, Levy S, Rao S, Zerwekh JE, Sudhaker Rao D (2009) Unusual mid-shaft fractures during long term bisphosphonate therapy. Clin Endocrinol (Oxf) 72:161-168.
32. Ing-Lorenzini K, Desmeules J, Plachta O, Suva D, Dayer P, Peter R (2009) Low-energy femoral fractures associated with the longterm use of bisphosphonates: a case series from a Swiss university hospital. Drug Saf 32:775-785.
33. Kwek EB, Goh SK, Koh JS, Png MA, Howe TS (2008) An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy? Injury 39:224-231.
34. Lenart BA, Lorich DG, Lane JM (2008) Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med 358:1304-1306. (Pubitemid 351439247)
35. Neviaser AS, Lane JM, Lenart BA, Edobor-Osula F, Lorich DG (2008) Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma 22:346-350. (Pubitemid 351630250)
36. Lee P, van der Wall H, Seibel MJ (2007) Looking beyond low bone mineral density: multiple insufficiency fractures in a woman with post-menopausal osteoporosis on alendronate therapy. J Endocrinol Invest 30:590-597. (Pubitemid 47577812)
37. Cheung RK, Leung KK, Lee KC, Chow TC (2007) Sequential nontraumatic femoral shaft fractures in a patient on long-term alendronate. Hong Kong Med J 13:485-489. (Pubitemid 351206686)
38. Goh SK, Yang KY, Koh JS,Wong MK, Chua SY, Chua DTC, Howe TS (2007) Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg Br 89:349-353. (Pubitemid 46563912)
39. Giusti A, Hamdy NAT, Papapoulos SE (2010) Atypical fractures of the femur and bisphosphonate therapy. A systematic review of case/case series studies. Bone 47:169-180.
40. Giusti A, Hamdy NAT, Dekkers OM, Ramautar SR, Dijkstra PDS, Papapoulos SE (2011) Atypical fractures and bisphosphonate therapy: a cohort study of patients with femoral fracture with radiographic adjudication of fracture site and features. Bone 48:966-971